Sign In
Buy IGC
$0.268
+0.0079 (+3.04%)
At Close: Jul 20, 2026
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
09:00am, Wednesday, 23'rd Jul 2025
- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pha
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
09:00am, Monday, 21'st Jul 2025
POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scien
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
03:10pm, Thursday, 10'th Jul 2025
- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:I
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation
09:00am, Monday, 30'th Jun 2025
POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatmen
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
06:46pm, Friday, 27'th Jun 2025
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025
08:30am, Friday, 27'th Jun 2025
POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday,
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon
08:30am, Monday, 23'rd Jun 2025
POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon, Ok
Squarepoint Ops LLC Takes Position in IGC Pharma, Inc. (NYSEMKT:IGC)
03:36am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC acquired a new stake in shares of IGC Pharma, Inc. (NYSEMKT:IGC – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securiti
IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
09:30am, Thursday, 22'nd May 2025
POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALM
IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting
09:30am, Monday, 12'th May 2025
POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Ev
IGC Pharma Welcomes Strategic Investment from Advisors
09:30am, Thursday, 24'th Apr 2025
POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs
09:30am, Monday, 21'st Apr 2025
Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
09:30am, Tuesday, 08'th Apr 2025
POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial wit
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
09:00am, Tuesday, 01'st Apr 2025
POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitati
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
09:00am, Wednesday, 26'th Mar 2025
- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Com
